BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37017998)

  • 21. Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.
    Zhang Z; Pang J; Chen L; Chen J; Li J; Liu H; Wang J; Wu H; Liang Z
    Hum Pathol; 2022 Nov; 129():21-31. PubMed ID: 35977594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities.
    Nozzoli F; Lazar AJ; Castiglione F; Campanacci DA; Beltrami G; De Logu F; Caporalini C; Massi D; Roviello G
    Pathol Oncol Res; 2022; 28():1610237. PubMed ID: 35295613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
    Xu B; Haroon Al Rasheed MR; Antonescu CR; Alex D; Frosina D; Ghossein R; Jungbluth AA; Katabi N
    Histopathology; 2020 Feb; 76(3):375-382. PubMed ID: 31448442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NTRK Gene Fusion Detection in Atypical Spitz Tumors.
    Cappellesso R; Nozzoli F; Zito Marino F; Simi S; Castiglione F; De Giorgi V; Cota C; Senetta R; Scognamiglio G; Anniciello AM; Cesinaro AM; Mandalà M; Gianatti A; Valente MG; Valeri B; Sementa AR; Ricci C; Corti B; Roviello G; Dei Tos AP; Franco R; Massi D
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of the methods for detecting NTRK gene fusion variations in papillary thyroid carcinoma].
    Jiang YY; Chen H; Xu BL; Wang S
    Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):726-732. PubMed ID: 35922162
    [No Abstract]   [Full Text] [Related]  

  • 26. Limited Accuracy of Pan-Trk Immunohistochemistry Screening for
    Macerola E; Proietti A; Poma AM; Vignali P; Sparavelli R; Ginori A; Basolo A; Elisei R; Santini F; Basolo F
    Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort.
    Dong K; Yin L; Wang Y; Jia L; Diao X; Huang X; Zhou L; Lin D; Sun Y
    Hum Pathol; 2024 Jun; 148():87-92. PubMed ID: 38653403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of
    Solomon JP; Hechtman JF
    Cancer Res; 2019 Jul; 79(13):3163-3168. PubMed ID: 31196931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CANTRK: A Canadian Ring Study to Optimize Detection of NTRK Gene Fusions by Next-Generation RNA Sequencing.
    Stockley TL; Lo B; Box A; Corredor AG; DeCoteau J; Desmeules P; Feilotter H; Grafodatskaya D; Greer W; Hawkins C; Huang WY; Izevbaye I; Lépine G; Martins Filho SN; Papadakis AI; Park PC; Riviere JB; Sheffield BS; Spatz A; Spriggs E; Tran-Thanh D; Yip S; Zhang T; Torlakovic E; Tsao MS
    J Mol Diagn; 2023 Mar; 25(3):168-174. PubMed ID: 36586421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.
    Vingiani A; Lorenzini D; Conca E; Volpi CC; Trupia DV; Gloghini A; Perrone F; Tamborini E; Dagrada GP; Agnelli L; Capone I; Busico A; Pruneri G
    Cancer Biomark; 2023; 38(3):301-309. PubMed ID: 37545217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
    Hsiao SJ; Zehir A; Sireci AN; Aisner DL
    J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NTRK gene aberrations in triple-negative breast cancer: detection challenges using IHC, FISH, RT-PCR, and NGS.
    Zito Marino F; Buono S; Montella M; Giannatiempo R; Messina F; Casaretta G; Arpino G; Vita G; Fiorentino F; Insabato L; Sgambato A; Orditura M; Franco R; Accardo M
    J Pathol Clin Res; 2023 Sep; 9(5):367-377. PubMed ID: 37143440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
    Marchiò C; Scaltriti M; Ladanyi M; Iafrate AJ; Bibeau F; Dietel M; Hechtman JF; Troiani T; López-Rios F; Douillard JY; Andrè F; Reis-Filho JS
    Ann Oncol; 2019 Sep; 30(9):1417-1427. PubMed ID: 31268127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of
    Koopman B; Kuijpers CCHJ; Groen HJM; Timens W; Schuuring E; Willems SM; van Kempen LC
    Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of cancers with NTRK gene fusions.
    Gatalica Z; Xiu J; Swensen J; Vranic S
    Mod Pathol; 2019 Jan; 32(1):147-153. PubMed ID: 30171197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant.
    Wu S; Liu Y; Shi X; Zhou W; Zeng X
    Dig Liver Dis; 2023 Dec; 55(12):1757-1764. PubMed ID: 37142453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.
    Chou A; Fraser T; Ahadi M; Fuchs T; Sioson L; Clarkson A; Sheen A; Singh N; Corless CL; Gill AJ
    Mod Pathol; 2020 May; 33(5):924-932. PubMed ID: 31792356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
    Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
    Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying patients with NTRK fusion cancer.
    Solomon JP; Benayed R; Hechtman JF; Ladanyi M
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.